Summary of the Conference Call for 亚辉龙 Company Overview - **Company**: 亚辉龙 (YHLO) - **Industry**: In Vitro Diagnostics (IVD) Key Financial Performance - **2024 Total Revenue**: 1.772 billion CNY, up 26.13% YoY - **2025 Q1 Revenue**: 418 million CNY, down 3.13% YoY - **Non-COVID Related Revenue (2024)**: 1.672 billion CNY, up 24.11% YoY - **Non-COVID Related Revenue (2025 Q1)**: 345 million CNY, up 1.09% YoY - **Overseas Non-COVID Related Revenue Growth**: 64.78% in 2024, 46.53% in 2025 Q1 [2][3] Profitability Metrics - **2024 Gross Margin**: 65.15%, up 8.58 percentage points YoY - **2025 Q1 Gross Margin**: 58.87%, down 2.9 percentage points YoY - **Chemical Luminescence Reagent Gross Margin**: 81.75% in 2024, down 1.2 percentage points YoY [2][5] Expense Management - **2024 Sales Expenses**: Increased by 9.94% - **2024 R&D Expenses**: Increased by 6.16%, R&D expense ratio at 16.74% - **2025 Q1 Sales Expenses**: Increased by 52% - **2025 Q1 Management Expenses**: Increased by 176% - **2025 Q1 R&D Expenses**: Decreased by 20.78% [2][6] Product Performance - **Automated Chemical Luminescence Immunoassay Analyzer Revenue (2024)**: 1.522 billion CNY, up 30.27% - **Overseas Revenue for Analyzers**: Increased by 69.1% [2][7] Installation and Market Coverage - **2024 New Installations of Self-produced Analyzers**: 2,662 units, with overseas growth of 80.56% - **Total Installations by 2025 Q1**: Over 11,340 units - **Coverage of Medical Institutions**: Over 6,090 domestic medical institutions, with a 70% coverage rate in top-tier hospitals [3][10][8] Innovations and R&D - **AI Medical Innovations**: Development of an AI-based indirect immunofluorescence ANA interpretation system with 91.3% accuracy and a false negative rate below 0.3% [12][13] - **Diabetes Management Platform**: Collaboration with Jiangsu Provincial People's Hospital to enhance diabetes diagnosis efficiency [14] Market Challenges and Strategies - **IVD Industry Pressures**: Challenges from DRG implementation, inspection mutual recognition, and healthcare cost control policies [17] - **Response to DRG Policy**: Adjusting strategies to maintain stable growth despite reduced testing volumes [18][19] Future Outlook - **Overseas Business Growth**: Expected to maintain over 50% growth in 2025 Q1, with a focus on non-US markets [15][36] - **Long-term Goals**: Aim to become a leading domestic brand in the immunodiagnostics field within five years and a global leader in ten years [38] Regulatory and Market Dynamics - **Impact of Tariff Policies**: Potential for increased domestic brand adoption due to tariff impacts on imports [20][30] - **Drug Centralized Procurement**: Implementation across provinces, providing opportunities for domestic brands [31] Conclusion - **Strategic Focus**: Emphasis on innovation, market expansion, and maintaining competitive advantages through AI and product development in the IVD sector [21][22][24]

21世纪经济报道记者 唐唯珂 广州报道 据新华社消息，4月以来，美国政府宣布对中国输美商品征收"对等关税"的税率进一步提高至125%。经国务院批准，国务院关税税则委员会公布公告，自 2025年4月12日起，调整《国务院关税税则委员会关于调整对原产于美国的进口商品加征关税措施的公告》（税委会公告2025年第5号）规定的加征关税税 率，由84%提高至125%。 达安基因、易瑞生物等企业明确表示没有对美国的产品出口，因此不受关税政策直接影响；而新产业、圣湘生物、亚辉龙等公司来自美国的营收占比普遍不 足1%，业务重心分布在欧洲、拉美、中东和东南亚等地区，使得关税调整对其海外业务冲击有限。 此外，部分企业如上海太阳生物已实现原料国产化或供应链自主可控，进一步降低了进口依赖带来的风险。整体来看，IVD行业并未出现大规模负面影响， 展现出较强的抗风险能力。 打破进口依赖 IVD行业的技术依赖呈现出明显的金字塔结构：在高端设备的应用逐渐普及的同时，某些关键原材料却依赖进口。以化学发光仪为例，国内70%以上的磁微 粒化学发光设备的核心光学部件依赖进口，而核酸提取试剂中的关键酶原料也有90%来自欧美供应商。 此前即有分析人士指出 ...